VYVGART (Argenx Australia Pty Ltd)
Product name
VYVGART
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
119 (255 working days)
Active ingredients
efgartigimod alfa
Registration type
NCE/ NBE
Indication
Vyvgart is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.